CAP 002 Viral set point and clinical progression in HIV-1 subtype C infection: the role of immunological and viral factors during acute and early infection Salim Abdool Karim Ongoing
CAP 005 TB Recurrence upon Treatment with HAART Kogie Naidoo Ongoing
CAP 006 Ancillary study to CAP 002 to assess women who have seroconverted after using tenofovir gel Salim and Quarraisha Abdool Karim Ongoing
CAP 007 Reducing HIV in Adolescents (RHIVA): A proof of concept cluster randomised controlled trial to evaluate the impact of cash transfer in schools receiving the essential package to reduce HIV infection in young women in KwaZulu-Natal, South Africa Quarraisha Abdool Karim Completed: Busy with data analysis
CAP 008 Open-Label Randomized Controlled Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision through Family Planning Services in KwaZulu-Natal, South Africa Quarraisha Abdool Karim / Leila Mansoor Ongoing
CAP 009 Open Label Randomized Controlled Trial to Assess the Impact of prophylactic exposure to tenofovir gel on the efficacy of subsequent tenofovir-containing antiretroviral therapy on viral suppression Nivashnee Naicker and Anushka Naidoo Ongoing
CAP 052 CAT Paediatric ARV Programme Kogie Naidoo Ongoing
CAP 053 CAPRISA AIDS Treatment Programme Kogie Naidoo Ongoing
CAP 055 Temporal trends in HIV infection in rural KwaZulu-Natal - implications for research and programmatic priority setting Ayesha Kharsany Ongoing
CAP 062 Field Based DOT for TB and HIV in the Welbedacht sub-district Kogie Naidoo Completed: Busy with data analysis
CAP 067 Tenofovir interaction with MDR drugs Nesri Padayatchi Data analysis stage
CAP 069 CAPRISA Medical Male Circumcision Programme Quarraisha Abdool Karim Ongoing
IMPAACT 1077BF Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere) Daya Moodley Ongoing
IMPAACT P1084s Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Daya Moodley Ongoing
MTN 020 A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 infection in Women Gonoasgarie Nair (Lulu) Ongoing
MTN 015 Ancillary Study An Observational Cohort Study of Women following HIV-1 Seroconversion in Microbicide Trials Gonoasgarie Nair (Lulu) Ongoing
MTN 016 Ancillary Study HIV Prevention Agent Pregnancy Exposure Registry: EMBRACE Study Gonoasgarie Nair (Lulu) Ongoing
AACTG A5290 A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifampin-Based Tuberculosis Treatment versus a Standard-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifabutin-Based Tuberculosis Treatment with or without Raltegravir in HIV-1-Infected Persons (A290) Requiring Treatment for Active TB and HIV Nesril Padayatchi Awaiting regulatory approval
AACTG A5273 Multicenter Study of Options for SEcond-Line Effective Combination Therapy (SELECT – A5273) Nesril Padayatchi Awaiting regulatory approval
AACTG A5279 Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection Nesril Padayatchi In-site training
AACTG A5304 Controlled comparison of two moxifloxacin containing treatment shortening regimens with the standard regimen in pulmonary tuberculosis Nesril Padayatchi In follow up phase
AACTG A5274 Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens Nesril Padayatchi Ongoing
AACTG A5288 Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE) Nesril Padayatchi Awaiting regulatory approval
INSIGHT FLU002 An International Observational Study to Characterize Adults with Influenza Nesril Padayatchi Ongoing

Centre for the AIDS Programme of Research in South Africa

CAPRISA was created in 2001 and formally established in 2002 under the NIH-funded Comprehensive International Program of Research on AIDS (CIPRA) by five partner institutions; University of KwaZulu-Natal, University of Cape Town, University of Western Cape, National Institute for Communicable Diseases, and Columbia University in New York. CAPRISA is a designated UNAIDS Collaborating Centre for HIV Prevention Research. The main goal of CAPRISA is to undertake globally relevant and locally responsive research that contributes to understanding HIV pathogenesis, prevention and epidemiology as well as the links between tuberculosis and AIDS care.